Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I –III Clinical Trials

ConclusionRisankizumab is characterized by dose-proportional, bi-exponential disposition with no difference in exposure between healthy subjects and patients with psoriasis. None of the covariates identified as being statistically correlated with risankizumab CL has a clinically meaningful impact on its exposure with the proposed psoriasis clinical regimen of 150  mg administered SC at weeks 0 and 4, and every 12 weeks thereafter.ClinicalTrials.gov IdentifiersNCT01577550, NCT02054481, NCT02596217, NCT02684370, NCT02672852, NCT02684357, NCT02694523.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research